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Abstract 
Small conductance calcium-activated potassium 
channel current, IKCa, has recently been characterized in 
atrial tissue and linked with atrial arrhythmogenesis. As 
IKCa does not contribute significantly to the ventricular 
action potential, there is great interest in developing 
pharmacological agents targeting these channels. 
However, experimental data so far have presented 
conflicting evidence as to whether IKCa inhibition is pro- or 
anti-arrhythmic. 
We have created a new formulation for IKCa, which we 
included in recently developed heterogeneous and 
anisotropic 3D canine atrial models. These were applied 
to investigate the effect of IKCa blockade compared to 
inhibition of other potassium currents: IKr and IKur. 
Blocking IKCa led to the termination of AF in the 3D 
atrial model, in contrast to blockades of IKur or IKr. 
Blocking IKCa prolonged action potential duration, APD, 
by at least 20 ms in all atrial cell types, whereas IKr or IKur 
blocks did not increase APD by more than 10 ms, thus 
explaining IKCa’s effectiveness in terminating AF. 
Nevertheless, the blockade of IKCa also led to an 
increase in APD dispersion, which is expected to be pro-
arrhythmic. In cases when the APD dispersion effects 
dominate over the APD prolongation, the blockade of IKCa 
is expected to be pro-arrhythmic, as seen in experimental 
models of non-remodelled canine atria. 
 
1. Introduction 
Atrial fibrillation (AF) is the most common sustained 
cardiac arrhythmia, affecting 3% of the adult population of 
developed countries. AF is associated with increased 
morbidity and mortality and its incidence is expected to 
rise in the near future, making it an urgent and important 
health problem [1]. 
Although anti-arrhythmic drugs (AADs) are the first 
line therapy for recent onset AF, their cardioversion 
efficacy can be as low as 50% [1]. AADs often carry 
significant side effects, namely the potential to induce life-
threatening ventricular arrhythmias. These pro-arrhythmic 
side effects can be minimised if AADs are designed to 
target atrial-selective ionic channels, which have a 
negligible contribution to the ventricular action potential. 
One of such targets is the K+ ultra-rapid delayed rectifier 
current, IKur, which is expressed in human atrial cells, but 
not in human ventricles [2]. This is in contrast with the 
rapid delayed rectifier current, IKr, which is ubiquitous 
throughout the heart and the blockade of which may lead 
to life-threatening Torsade de Pointes [2]. 
Recently, ionic current carried by small-conductance 
calcium-dependent K+ channels, IKCa, has been 
characterised in human and canine atrial cells, but, 
significantly, not in ventricular myocytes, making IKCa a 
potentially desirable target of anti-arrhythmic drug action 
in AF. Genomic associations between IKCa and AF have 
also been established [3].  
Although blocking IKCa is known to increase the action 
potential duration (APD) in canine atrial cells [3]–[6], 
there is some controversy as to whether its blockade is pro- 
or anti-arrhythmic. Blocking IKCa has been found to 
facilitate the initiation of atrial arrhythmias [3], [6], by 
increasing both APD and APD heterogeneity in the canine 
left atrium (LA). Other studies have instead found that IKCa 
blockade, through prolongation of APD, led to reduced AF 
duration [4] and AF termination [5]. It is also at the 
moment not clear whether IKCa is overexpressed in the 
presence of AF remodelling [4] or not [7]. 
In this paper, we aim to reconcile the disparate 
experimental findings about IKCa’s effect on AF using 
insights from computational models. To this end, we 
introduce a new mathematical formulation for IKCa and 
include it in our recently developed canine atrial cell 
models [8]. We use these updated canine models to 
investigate the effect on APD of blockades of IKr, IKur and 
IKCa in several atrial remodelling conditions. We then 
determine the effectiveness of these blockades in realistic 
3D canine atrial models [8] and interpret these findings in 
the light of the drugs’ effects on APD and APD dispersion 
across the entire atria, using the formalism previously 
applied to investigate the effectiveness of multi-channel-
blocking AADs [8]. 
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3. Methods 
3.1. Canine Model of Atrial Fibrillation 
In this study we used the 3D canine model successfully 
employed to study the efficacy of AADs in atrial 
fibrillation [8], [9]. This model includes a realistic canine 
atrial geometry and myofibre orientations derived from 
micro computed tomography [10]. It also includes four 
region-specific electrophysiological models and can easily 
incorporate different degrees of AF-induced ionic and 
structural remodelling [8]. 
As in the previous study, we solved the monodomain 
equation in a central finite differences setting with t = 5 
s and x = 0.3 mm. Conditions mimicking AF were 
obtained by pacing with an S1-S2 protocol near the 
pulmonary veins (PV) in the presence of moderate or 
severe ionic remodelling (see [8], [9] for details). We 
additionally studied a situation of moderate remodelling in 
the presence of IKCa, according to the new mathematical 
formulation of this current presented below. 
 
3.2. Formulation of IKCa in Heart Failure 
The atrial IKCa was formulated as a time-independent 
passive K+ current whose conductance depends strongly on 
the intracellular calcium concentration, [Ca2+]i, following 
a Hill equation [11], [12]. Parameterization was achieved 
by fitting experimental data from isolated ventricular 
myocytes from HF patients [11], to give Equation (1): 
 
𝐼𝐾𝐶𝑎 =  𝑔𝐾𝐶𝑎  
[𝐶𝑎2+]𝑖
𝑛
[𝐶𝑎2+]𝑖
𝑛
+𝐾𝑑
𝑛 (𝑉𝑚 − 𝐸𝐾)               (1) 
 
with gKCa = 0.07 pA/pF, n = 5.0 and Kd = 3 x 10-4 mM. Vm 
is the transmembrane electrical potential, and EK is the 
reversal potential for K+ ions, typically around -87 mV.  
 
3.3. Modelling the Action of AADs 
The initial simulations of AF were run for 5 s, at which 
time each of the AADs was administered. Each drug action 
was responsible for an instantaneous 50% block of: 1) IKr; 
2) IKur or, when the model included it, 3) IKCa. The electrical 
activity of the atrial model was followed for 5s or until 
termination of all re-entrant activity.  
To shed light into the mechanisms through which AAD 
action is facilitated, we computed 90% action potential 
duration, ADP90, in baseline conditions (canine models [8] 
with IKCa)  and in the presence of 50% block of either: 1) 
IKr, 2) IKur and 3) IKCa. This was performed for a basic cycle 
length (BCL) of 500 ms in single-cells and in realistic 3D 
atrial models. In the latter case, the canine atrial model was 
paced twice at 150 ms near the left superior PV before 
APD in each voxel of the model. 
4. Results 
4.1. AAD effects in a 3D Model of AF 
In our AF model of moderate ionic remodelling, IKr 
blockade did not have a significant effect on AF, whereas 
IKur blockade led to the creation of an additional rotor in 
the right atrium (RA). In the advanced AF model, AF was 
sustained by four rotors in total (Figure 1). Neither IKr nor 
IKur blockade had a significant effect in any of the rotors. 
The IKCa blockade terminated AF within 500 ms. Both IKr 
and IKur blockades increased the complexity of AF 
activations, leading to the formation of an additional rotor 
in each atrial appendage (RAA and LAA). The outcomes 
of these simulations are summarised in Table 1. 
 
Figure 1: Maps of transmembrane voltage, Vm (left) and 
intracellular calcium concentration, [Ca2+]i (right), in the 
canine atrial model just before the application of the 
AADs. Black arrows mark the direction of the re-entrant 
circuits driving AF in the model. 
 
 
Table 1. Description of the observed re-entrant activity 
after administration of three different anti-arrhythmic 
drugs in different conditions. 
 
AAD 
(Channel 
Blocked 
by 50%) 
 
Moderate 
Ionic 
Remodeling 
 
Severe 
Ionic 
Remodeling 
Moderate 
Ionic 
Remodeling 
with IKCa 
 
IKr 
 
No change. 
 
No change. 
The rotor 
divides into 
two. 
 
IKur 
A new rotor 
appears in 
the RAA. 
 
No change. 
The rotor 
divides into 
two. 
 
IKCa 
  
- 
 
- 
All activity 
is terminated 
at < 500 ms. 
 
4.2. Effect on APD and APD Heterogeneity 
To interpret the different behaviour of the re-entrant 
activity in the presence of the AADs in the 3D simulations, 
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we analysed the effect of the AADs on atrial refractoriness, 
as measured by APD90. Figure 2a shows the increase in 
single-cell APD90 values for different cell types (RA, LA, 
Bachmann’s bundle and PV) in the presence of the IKCa 
formulation of Eq. (1) for the two levels of ionic 
remodelling. It is clear that the IKCa block led to the greatest 
rise in APD90, with IKr and IKur having a nearly insignificant 
effect on APD at the studied pacing rates. The IKCa block 
also enhances the heterogeneity in APD across cell types, 
particularly for conditions of moderate remodelling. 
 
Figure 2. Effect of the 50% blockade of different ionic channels on APD90 values for the atrial canine model [8] in the 
presence of IKCa (Eq. (1)) for moderate ionic remodelling. a) Increase in single-cell APD90 for each cell type for each AAD 
(BCL: 500 ms). b) Histogram of APD90 in atrial tissue in baseline conditions and after the administration of each AAD 
(BCL: 150 ms). c) APD90 maps in baseline conditions and in the presence of each ionic channel blocker (BCL: 150 ms). 
 
3. Conclusions 
In this paper, we extended the computational framework 
previously presented to study the action of AADs in a 
realistic 3D model of AF to include the small-conductance 
calcium-dependent K+ channel recently characterized in 
atrial myocytes. Using the new model, we found that 
blocking IKCa was very effective at terminating AF, in 
contrast to inhibition of either IKur or IKr, which were pro-
arrhythmic in these circumstances (Table 1). Even in the 
absence of IKCa, blocking IKur or IKr did not lead to 
termination in either of the investigated stages of AF 
remodelling (Table 1). 
The differences in the effectiveness of these drugs can 
be explained by their effect on atrial APD. We found that 
blocking IKCa led to both an increase in APD and APD 
dispersion (Figure 2), in contrast with blocks of either IKr 
or IKur, which hardly affected APD in the analysed 
conditions. We thus hypothesise that the effectiveness of 
the IKCa block lies in the increase in APD (and therefore 
wavelength) that it generates. As in Moe’s classical theory, 
this leads to a decrease in the critical volume available to 
the existing re-entrant circuits, terminating them [13].  
In the analysed circumstances, the substantial increase  
 
in APD (of more than 60 ms, Figure 2a) brought about by 
IKCa’s block trumps the concomitant pro-arrhythmic 
increase in APD dispersion. It is likely that the APD90 
dispersion induced by IKCa is, at least in part, mediated by 
the very heterogeneous distribution of Cai across the atria, 
as seen in Figure 1. 
This is in contrast to the AAD actions studied 
previously [8], whose effectiveness was dominated by 
their effect on APD dispersion over APD prolongation. We 
propose that the effectiveness of IKCa blockers may depend 
on the balance between these two anti-arrhythmic and pro-
arrhythmic effects. In cases when the APD prolongation 
dominates (as remodelling conditions in the current study), 
a block of IKCa is likely to be beneficial. This agrees with 
anti-arrhythmic effects of IKCa blockade observed in dogs 
exposed to prolonged atrial pacing [4]. However, if the 
dispersion in APD it induces is the dominant effect, it is 
likely that an APD block may be pro-arrhythmic, as seen 
non-remodelled canine atria [3]. These hypotheses, as well 
as the congruent earlier ones [14], will be tested in greater 
detail in future computational studies.  
The current study has some limitations. The AAD 
actions do not model the action of known compounds, 
instead focusing on mechanisms of drug action. Ion 
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channel state-dependent binding is therefore not taken into 
account. We have additionally assumed that the drug 
action was instantaneous, which is a simplification.  
In summary, the current study presents a novel 
formulation for IKCa, which was incorporated into existing 
state of the art canine atrial models. We use these updated 
electrophysiology models to investigate the effectiveness 
of IKCa blockade in comparison to blockades of other K+ 
channels: IKr and IKur. We explain the superiority of IKCa 
blockade by showing how it leads to an increase in APD. 
The IKCa blockade causes, nevertheless, an increase in APD 
dispersion, which, in some circumstances, may be pro-
arrhythmic, as has been shown in experimental studies.  
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